Phenotypes Associated with This Genotype

Genotype
MGI:5897809

• Allelic Composition: Mob1a^tm1.1Asuz/Mob1a^tm1.1Asuz; Mob1b^{Gt(CC0690)Wtsi}/Mob1b^{Gt(CC0690)Wtsi}; Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺
• Genetic Background: B6.Cg-Mob1b^{Gt(CC0690)Wtsi} Mob1a^tm1.1Asuz Speer6-ps1^{Tg(Alb-cre)21Mgn}

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

premature death ( J:228499 )

• all mice are dead by 60 weeks

postnatal lethality, incomplete penetrance ( J:228499 )

• the first mice die at P14 and more than half of mice die by P21

liver/biliary system

liver/biliary system phenotype ( J:228499 )

N • mice exhibit normal liver structure at P0

increased hepatocyte proliferation ( J:228499 )

• 3 times in controls

abnormal cholangiocyte morphology ( J:228499 )

• at P7, mice exhibit increased immature cholangiocyte-like and oval cells that becomes massive at P10 especially in periductal and intraductal locations

• mild hepatocholangiocellular hyperplasia at P21

enlarged liver ( J:228499 )

• massive

increased hepatocyte number ( J:228499 )

• 5 times greater than in control mice at P14

liver fibrosis ( J:228499 )

increased hepatobiliary system tumor incidence ( J:228499 )

• combined hepatocellular and cholangiocarcinomas, increased hepatocellular carcinoma, liver adenoma incidence or cholangiocarcinoma in 8 of 10 mice surviving beyond P21 by age 15 weeks

• combined hepatocellular and cholangiocarcinomas in 13 of 22 mice at week 60

• with lung metastasis after 40 weeks of age

increased cholangiocarcinoma incidence ( J:228499 )

• intrahepatic cholangiocellular carcinoma in 8 of 10 mice surviving beyond P21 by age 15 weeks

• in 2 of 22 mice at week 60

increased hepatocellular carcinoma incidence ( J:228499 )

• in mice surviving beyond P21 by age 15 weeks

• in 4 of 22 mice at week 60

increased liver adenoma incidence ( J:228499 )

• in mice surviving beyond P21 by age 15 weeks

abnormal bile duct physiology ( J:228499 )

• cholangiocytes proliferation is increased 4 times compared with controls

• however, there is no increase in apoptosis

jaundice ( J:228499 )

neoplasm

increased hepatobiliary system tumor incidence ( J:228499 )

• combined hepatocellular and cholangiocarcinomas, increased hepatocellular carcinoma, liver adenoma incidence or cholangiocarcinoma in 8 of 10 mice surviving beyond P21 by age 15 weeks

• combined hepatocellular and cholangiocarcinomas in 13 of 22 mice at week 60

• with lung metastasis after 40 weeks of age

increased cholangiocarcinoma incidence ( J:228499 )

• intrahepatic cholangiocellular carcinoma in 8 of 10 mice surviving beyond P21 by age 15 weeks

• in 2 of 22 mice at week 60

increased hepatocellular carcinoma incidence ( J:228499 )

• in mice surviving beyond P21 by age 15 weeks

• in 4 of 22 mice at week 60

increased liver adenoma incidence ( J:228499 )

• in mice surviving beyond P21 by age 15 weeks

homeostasis/metabolism

increased circulating bilirubin level ( J:228499 )

integument

abdomen swellings ( J:228499 )

• due to enlarged liver

cellular

increased hepatocyte proliferation ( J:228499 )

• 3 times in controls

endocrine/exocrine glands

abnormal cholangiocyte morphology ( J:228499 )

• at P7, mice exhibit increased immature cholangiocyte-like and oval cells that becomes massive at P10 especially in periductal and intraductal locations

• mild hepatocholangiocellular hyperplasia at P21

growth/size/body

enlarged liver ( J:228499 )

• massive